Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
Conditions: BRAF V600E Mutation Present; Papillary Craniopharyngioma Interventions: Drug: Vemurafenib; Drug: Cobimetinib; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Not yet recruiting - verified July 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Craniopharyngioma